General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis

News

Article

August 17, 2024

Derm In The News: August 11-17

Author(s):

Keep up with the latest headlines in dermatology from the past week, including honoring the teenage inventor of a soap to treat skin cancer, the US FDA's approval of nemolizumab for prurigo nodularis, and more.

USA Today: 15-year-old who created soap that could treat skin cancer named Time's 2024 Kid of the Year

Heman Bekele, a 15-year-old from Annandale, Virginia, was recognized as Time's 2024 Kid of the Year for developing a soap that has the potential to improve skin cancer treatment. His product aims to provide a more accessible method for delivering medication to treat skin cancers, including melanoma. Previously, Bekele was honored as America's Top Young Scientist by 3M and Discovery Education in 2023, earning a $25,000 prize.

FiercePharma: Itching for leadership in 'therapeutic dermatology,' Galderma wins FDA nod for Nemluvio to treat prurigo nodularis

Galderma Pharma's Nemluvio (nemolizumab) received FDA approval for treating prurigo nodularis. This new monoclonal antibody, administered monthly via a prefilled pen, targets IL-31 to alleviate symptoms. The approval follows positive phase 3 trial results showing significant improvements in itch, skin clearance, and sleep disturbance compared to placebo.

Read more from Dermatology Times.

Patient-Forward Rundown

Top headlines from this week to share with your patients:

Morningstar: Candela Announces FDA-Clearance of New Indication for Matrix Multi-Application Radiofrequency Skin Platform

Candela Corporation received FDA clearance for its Matrix platform, specifically expanding the Matrix Pro RF microneedling applicator's indications to include facial wrinkle reduction. The Matrix Pro applicator, now cleared for use on Fitzpatrick skin types I-IV, employs radiofrequency microneedling to stimulate collagen and elastin production, enhancing skin smoothness and reducing wrinkles. This system features Depth Intelligence technology for precise energy delivery and real-time tissue impedance monitoring. The approval is based on a study showing significant improvements in wrinkle appearance and high patient satisfaction.

Read more from Dermatology Times.

GlobeNewswire: Derm-Biome Pharmaceuticals to develop skincare treatment that promotes skin health and longevity

Derm-Biome Pharmaceuticals Inc. has developed a new skin care treatment targeting the root causes of skin aging, such as chronic inflammation and cellular damage. Their novel compounds, which show anti-inflammatory, antioxidant, and antimicrobial properties, have demonstrated significant improvements in skin appearance in preclinical studies. The lead compound inhibits inflammatory cytokines, boosts collagen production, and activates antioxidant pathways, potentially offering protection against UV-induced skin aging. Upcoming preclinical studies will further explore its efficacy in mimicking long-term sun exposure effects.

VUMC News: Nicole Ward honored by dermatological society

The European Society for Dermatological Research (ESDR) will award honorary membership to 3 new members at its upcoming annual meeting in Lisbon. Nicole Ward, PhD, a professor at Vanderbilt University Medical Center known for her research on chronic inflammatory skin diseases and their links to cardiovascular conditions, is among the honorees. Ward has made significant contributions to understanding psoriasis and was the first non-MD and youngest recipient of the Eugene M. Farber Lecture. The other new honorary members are Chris Griffiths, OBE, MD, president of the ESDR and director of the Center for Dermatology Research at the University of Manchester, and Kenji Kabashima, MD, PhD, a professor at Kyoto University.

Have you seen any dermatology headlines this week that we may have missed? Share with us by emailing our team at DTEditor@mmhgroup.com.